Taking a daily birth control pill is supposed to make it easier for women to insure that contraception works all the time. A new lawsuit now says that, for many women, certain oral contraceptives resulted in unwanted pregnancies, and some plaintiffs are demanding reimbursement for the full cost of raising the unplanned children.

The problem involves packages of birth control pills made by the generic drug company Qualitest Pharmaceuticals, according to the Huffington Post. More than 110 women from 13 states are suing the company in a Philadelphia court, alleging that mislabeled oral contraceptives led them to believe that they could not become pregnant during times in their menstrual cycles when they were actually fertile.

Qualitest is a division of the Irish drug maker Endo Pharmaceuticals, which has its U.S. headquarters in Pennsylvania.

Birth control pills work by providing a dose of female hormones during the menstrual cycle, with the result that women are prevented from producing viable eggs. While the hormonal pills only need to be taken during a few days each month, for decades most drug companies have sold oral contraceptives as a daily pill, since it is challenging for women to know exactly when to start and stop taking the hormone each month.

The packaging is supposed to take care of the dosing problem, with the pre-packaged mix of sugar and hormonal pills automatically set for the proper daily dosing. However, a packaging mix-up for some Qualitest products meant that some women were taking sugar pills when they should have been getting the hormone.

Qualitest issued a voluntary recall of the packages in 2011. The lawsuits call the packaging “defectively and dangerously designed,” and some of the suits are seeking the full cost of child-raising through age eighteen.

In response to the charges, a Qualitest statement noted that the recall was four years ago, and claimed that it could only identify one women who had purchased a faulty package. Two previous attempts to bring class-action cases against the company, one in Georgia and another in California, were denied by the courts.